Medexus Pharmaceuticals Inc. (TSE:MDP) Receives C$5.49 Average Target Price from Brokerages

Medexus Pharmaceuticals Inc. (TSE:MDP) has been assigned a consensus recommendation of “Buy” from the seven analysts that are presently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation, one has assigned a buy recommendation and four have issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is C$5.49.

Separately, Alliance Global Partners raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, August 11th.

Medexus Pharmaceuticals Price Performance

Shares of MDP opened at C$2.95 on Wednesday. The firm’s 50 day simple moving average is C$2.92 and its 200 day simple moving average is C$2.81. The company has a market capitalization of C$66.05 million, a P/E ratio of 14.11 and a beta of 1.96. Medexus Pharmaceuticals has a 1-year low of C$1.71 and a 1-year high of C$5.56.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.